Current Report Filing (8-k)
September 18 2020 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
September 16, 2020
INTEC PHARMA LTD.
(Exact name of registrant as specified
in its charter)
Israel
|
|
001-37521
|
|
N/A
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
12 Hartom St.
Har Hotzvim
|
|
|
Jerusalem, Israel
|
|
9777512
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
+ 972-2 - 586-4657
|
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange
on which registered
|
Ordinary Shares, no, par value
|
|
NTEC
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On September 16, 2020, the Board of Directors of Intec Pharma Ltd. (the “Company”), upon recommendation of its Compensation Committee, approved an executive retention award to each of Nir Sassi, the Company’s Chief Financial Officer and Walt A. Linscott, the Company’s Chief Business Officer, of 100,000 options to purchase ordinary shares of the Company pursuant to the Company’s 2015 Equity Incentive Plan. The foregoing options have an exercise price of $0.3215 per share, have a seven-year term and, subject to the executive’s continued employment with the Company on the vesting date, vest on December 31, 2021.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: September 18, 2020
|
INTEC PHARMA LTD.
|
|
|
|
By:
|
/s/ Nir Sassi
|
|
|
Nir Sassi
|
|
|
Chief Financial Officer
|
2
00-0000000
false
0001638381
0001638381
2020-09-16
2020-09-16
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Sep 2023 to Sep 2024